Abstract: The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.
Type:
Grant
Filed:
January 16, 2009
Date of Patent:
November 9, 2010
Assignee:
Immunex Corporation
Inventors:
Kristine M. Kim, Steven R. Wiley, Randal R. Ketchem, William C. Fanslow, III
Abstract: The invention relates to antibodies that bind to antigens, such as antigens associated with hyperproliferating cells, and methods of treating hyperproliferative disorders. The invention antibodies are useful for treating hyperproliferative disorders, such as neoplasia.
Type:
Grant
Filed:
September 25, 2008
Date of Patent:
November 9, 2010
Assignee:
Shantha West, Inc.
Inventors:
Subhra Chakrabarti, Sonjoy Mukerjee, Mark C. Glassy
Abstract: The invention relates to a medicament against tumors and their metastases, which preferentially settle in bone tissue, comprising as active ingredient at least one binding molecule which binds to bone sialoprotein or a fragment thereof in serum or plasma.
Type:
Grant
Filed:
June 12, 2002
Date of Patent:
November 2, 2010
Assignee:
Armbruster Biotechnology GmbH
Inventors:
Franz Paul Armbruster, Markus Karmatschek, Franz Werner Nader, Ulf Joerg Forssmann, Mats Paulsson, Martin R. Berger
Abstract: This invention relates to a gene encoding RTVP that has been shown to be up-regulated by p53 using differential display-PCR and subsequently by co-transfection studies. RTVP-1 mRNA is abundant in normal mouse and human prostatic epithelial cells and primary tumors, but is significantly down regulated in metastatic mouse and human prostate cancer. In prostate cancer cells overexpression of the mouse RTVP-1 gene (mRTVP-1) induced apoptosis that was accompanied by increased caspase 8, 9 and 3 activities. mRTVP-1-stimulated apoptosis was also associated with increased levels of bax, bad and activated BID; reduced levels of bcl-2 and bcl-XL; and cytosolic cytochrome c accumulation. Adenoviral-vector-mediated mRTVP-1 expression lead to potent growth suppression and antimetastatic activities in an orthotopic mouse model of prostate cancer in vivo. These therapeutic activities were associated with anti-angiogenic effects and importantly a local and systemic immune response.
Abstract: An objective of the present invention is to provide methods of screening for novel compounds that exhibit anticancer activity. The screening methods of the present invention comprise using serine/threonine kinase Pim-1, or partial peptides or salts thereof.
Abstract: The present invention relates to novel sequences for use in detection, diagnosis and treatment of cancers, especially lymphomas. The invention provides cancer-associated (CA) polynucleotide sequences whose expression is associated with cancer. The present invention provides CA polypeptides associated with cancer that are present on the cell surface and present novel therapeutic targets against cancer. The present invention further provides diagnostic compositions and methods for the detection of cancer. The present invention provides monoclonal and polyclonal antibodies specific for the CA polypeptides. The present invention also provides diagnostic tools and therapeutic compositions and methods for screening, prevention and treatment of cancer.
Abstract: A new polypeptide is disclosed that is specifically detected in the cells of the prostate, termed Novel Gene Expressed in Prostate (NGEP). Polynucleotides encoding NGEP are also disclosed, as are vectors including these polynucleotides. Host cells transformed with these polynucleotides are also disclosed. Antibodies are disclosed that specfically bind NGEP. Methods are disclosed for using an NGEP polypeptide, an antibody that specifically binds NGEP, or a polynucleotide encoding NGEP. Assays are disclosed for the detection prostate cancer. Pharamaceutical compositions including an NGEP polypeptide, an antibody that specifically binds NGEP, or a polynucleotide encoding NGEP are also disclosed. These pharmaceutical compositions are of use in the treatment of prostate cancer.
Type:
Grant
Filed:
November 13, 2002
Date of Patent:
October 19, 2010
Assignee:
The United States of America as represented by the Department of Health and Human Services
Inventors:
Ira H. Pastan, Tapan K. Bera, Curt Wolfgang, Byungkook Lee, James Vincent
Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies.
Type:
Grant
Filed:
June 2, 2005
Date of Patent:
October 19, 2010
Assignees:
Amgen Fremont Inc., Pfizer Inc.
Inventors:
Bruce D Cohen, Jean Beebe, Penelope E Miller, James D Moyer, Jose R Corvalan, Michael Gallo
Abstract: The present invention relates to methods of identifying the susceptibility of cells to reovirus infection by measuring constitutive ras-MAP signaling. The invention also pertains to methods using reovirus for the treatment of cellular proliferative disorders, and particularly cellular proliferative disorders wherein the proliferating cells exhibit constitutive MAPK phosphorylation, in mammals. In particular, the methods provide for reovirus treatment of mammals to treat proliferative disorders which include breast tumors, a subset of tumors in which mutation of the ras gene is not believed to play a significant role.
Abstract: Disclosed are a protein encoded by a gene having a nucleotide sequence represented by any of SEQ ID NOs: 1 to 65 or a fragment thereof, an antibody recognizing the protein or antigen-binding fragment thereof, and a polynucleotide having a sequence comprising at least 12 consecutive nucleotides of a nucleotide sequence represented by any of SEQ ID NOs: 1 to 65 or a nucleotide sequence complementary thereto. The gene and the protein of the invention is useful for diagnosing and treating cancer.
Abstract: The present invention relates to cDNA sequences from a region of amplification on chromosome 20 associated with disease. The sequences can be used in hybridization methods for the identification of chromosomal abnormalities associated with various diseases. The sequences can also be used for treatment of diseases.
Type:
Grant
Filed:
July 22, 2008
Date of Patent:
October 12, 2010
Assignees:
The Regents of The University of California, The Hospital for Sick Children
Inventors:
Joe W. Gray, Colin Conrad Collins, Soo-in Hwang, Tony Godfrey, David Kowbel, Johanna Rommens
Abstract: A method of diagnosing cancer comprising the identification of neoplastic molecular markers is disclosed. Tumor-related or neoplastic molecular markers are identified from samples taken from a subject and the molecular profile of those markers is determined. Based upon the neoplastic molecular marker profile of the subject, the tumor sub-type is ascertained and an appropriate treatment protocols initiated.
Abstract: Mutant LIGHT expressed in a tumor environment elicited high levels of chemokines and adhesion molecules, accompanied by massive infiltration of naïve T lymphocytes. Methods and compositions to elicit immune responses against tumors including tumor volume reduction and eradication of metastasis using mutant LIGHT are disclosed.
Abstract: The invention provides relatively short immunogenic peptides derived from CD19 and CD20 antigens, and biologically active variants thereof, which elicit an immune response. Nucleic acids encoding the immunogenic peptides and antibodies specific for the peptides are also provided. The immunogenic peptides can be included in pharmaceutical compositions, such as cancer vaccines, and used for the treatment of cancer.
Abstract: CASB7439 polypeptides and polynucleotides, immunogenic compositions comprising them and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing CASB7439 polypeptides and polynucleotides in diagnostics, and vaccines for prophylactic and therapeutic treatment of cancers, particularly colorectal, breast, and lung cancers, autoimmune diseases, and related conditions.
Type:
Grant
Filed:
August 28, 2003
Date of Patent:
October 12, 2010
Assignee:
GlaxoSmithKline Biologicals S.A.
Inventors:
Jean-Pol Cassart, Teresa Elisa Virginia Cabezon-Silva, Thierry Coche, Swann Romain Jean-Thomas Gaulis, Carlota Vinals Y De Bassols
Abstract: Methods and reagents for classifying tumors and for identifying new tumor classes and subclasses. Methods for correlating tumor class or subclass with therapeutic regimen or outcome, for identifying appropriate (new or known) therapies for particular classes or subclasses, and for predicting outcomes based on class or subclass. New therapeutic agents and methods for the treatment of cancer.
Type:
Grant
Filed:
January 14, 2008
Date of Patent:
October 12, 2010
Assignee:
Applied Genomics, Inc.
Inventors:
Brian Z. Ring, Douglas T. Ross, Robert S. Seitz
Abstract: A novel gene, designated MCT-1 (for Multiple Copies in T-cell malignancy), is provided. A protein encoded by MCT-1, designated MCT-1, is also provided. Antisense oligonucleotides complementary to or homologous with a portion of MCT-1, substantially purified MCT-1, and methods of determining whether a cell is a tumor cell are also provided. The invention also includes monoclonal and polyclonal antibody preparations which bind with specificity to MCT-1. The invention further includes methods of determining whether a compound or a gene product is a modulator of MCT-1 expression, a method of reducing MCT-1 expression in a cell, and a method of conferring a growth advantage on a cell.
Abstract: The present invention provides a method of treating cancer involving administering an insulin-like growth factor-1 receptor (IGF-1 receptor) agonist and an anti-cancer chemotherapeutic agent. Also provided are compounds for treating cancer comprising an IGF-1-receptor ligand coupled to an anti-cancer chemotherapeutic agent. Also provided are compounds for treating cancer comprising an insulin-receptor ligand coupled to an anti-cancer chemotherapeutic agent.
Abstract: Nucleic acid molecules modified to enhance recombinant protein, e.g., antibody, expression and/or reduce or eliminate mis-spliced and/or intron read-through (IRT) by-products are disclosed. The invention also provides methods for producing proteins devoid of mis-spliced and/or intron read-through by-products by the use of such vectors in host cells under cell culture conditions suitable for recombinant protein expression.
Type:
Grant
Filed:
October 5, 2005
Date of Patent:
October 5, 2010
Assignee:
Wyeth LLC
Inventors:
Martin S. Sinacore, Mark Leonard, Haley A. Laken, Jason Rouse
Abstract: The present invention features a novel combination therapy useful in the treatment of autoimmune disease that increases or maintains the number of functional cells of a predetermined type in a mammal by killing or inactivating autoimmune cells and re-educating the host immune system.